Arthritis

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

Retrieved on: 
Wednesday, May 8, 2024

“These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.

Key Points: 
  • “These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.
  • CX-904 Phase 1a dose escalation and optimization continue, with future enrollment focused on determining a recommended Phase 2 dose, or doses.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • These additional data will inform discussions with CytomX partner, Amgen, towards initiation of Phase 1b expansion cohorts in specific EGFR positive tumor types.

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 8, 2024

Initial data anticipated in 2025 -

Key Points: 
  • Initial data anticipated in 2025 -
    - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT -
    SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today reported first quarter 2024 financial results and provided a business update.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • The cash balance as of March 31, 2024, does not include the $10.0 million of Astellas milestone achievements earned in the first quarter of 2024.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Autoimmune Disease Diagnostics Market Research, Size, Global Forecasts 2024-2030: Robotics and AI, Autoantibody Assays and Genetic Testing, & Innovative Biomarkers Drive Expansion - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 9, 2024

The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.

Key Points: 
  • The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.
  • By product, the global autoimmune diseases diagnostics market is fragmented into Therapeutic & Monitoring Equipment, Diagnostics Equipment, and Drugs.
  • The global autoimmune diseases diagnostics market is segmented into Systemic Autoimmune Disease Diagnostics and Localized Autoimmune Disease Diagnostics.
  • By indication, the global autoimmune diseases diagnostics market is categorized into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Others.

Atlantis Orthopedics Selects eClinicalWorks Cloud EHR and healow to Improve Practice Efficiency and Enhance Patient Care

Retrieved on: 
Tuesday, May 7, 2024

eClinicalWorks® , the largest ambulatory cloud EHR, today announced that Florida-based Atlantis Orthopedics, has selected eClinicalWorks Cloud EHR and healow® patient engagement solutions to streamline operations and improve patient engagement.

Key Points: 
  • eClinicalWorks® , the largest ambulatory cloud EHR, today announced that Florida-based Atlantis Orthopedics, has selected eClinicalWorks Cloud EHR and healow® patient engagement solutions to streamline operations and improve patient engagement.
  • By leveraging the intelligent eClinicalWorks Cloud EHR and healow patient engagement solutions, the practice can enhance the patient experience and improve overall practice efficiency.
  • “We selected eClinicalWorks for a fully integrated cloud EHR and patient engagement solutions, facilitating quick access to patient information and improving the patient experience.
  • eClinicalWorks is designed to help healthcare providers optimize resources, focus on patient care, and reduce costs.

Ultrasound Neuromodulation Shows Promise to Treat Pulmonary Hypertension, Feinstein Institutes Research

Retrieved on: 
Tuesday, May 7, 2024

Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).

Key Points: 
  • Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).
  • View the full release here: https://www.businesswire.com/news/home/20240507538578/en/
    Feinstein Institutes’ Dr. Stavros Zanos is the senior author on the new bioelectronic medicine ultrasound paper.
  • The research adds to the growing scientific evidence of bioelectronic medicine and neuromodulation as an effective therapy to treat diseases with an inflammatory component.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

ROSEN, A TOP RANKED LAW FIRM, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation – ZTS

Retrieved on: 
Saturday, May 4, 2024

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24154 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24154 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Sterling Ridge Orthopaedic & Sports Medicine Sets Milestone with Dr. Paul Chin's Innovative Shoulder Replacement Surgery

Retrieved on: 
Thursday, May 2, 2024

Shoulder replacement surgery is a complex procedure to relieve pain and restore function to shoulders damaged by arthritis, severe fractures, or other debilitating conditions.

Key Points: 
  • Shoulder replacement surgery is a complex procedure to relieve pain and restore function to shoulders damaged by arthritis, severe fractures, or other debilitating conditions.
  • "We are immensely proud of Dr. Paul Chin's groundbreaking achievement," said Stacy Lund, Director of Operations at Sterling Ridge Orthopaedics & Sports Medicine.
  • "His innovative approach to shoulder replacement surgery demonstrates our clinic's commitment to delivering the highest quality of care through cutting-edge technology."
  • For more information about Sterling Ridge Orthopaedics & Sports Medicine and Dr. Paul Chin, please visit www.srosm.com or www.paulchinmd.com

New Guide Empowers Patients to Face Gout's Physical & Mental Toll

Retrieved on: 
Thursday, May 2, 2024

WASHINGTON, May 2, 2024 /PRNewswire/ -- The Alliance for Gout Awareness today released a resource guide to help patients navigate the physical and mental toll of gout, a form of arthritis that affects over 9 million Americans.

Key Points: 
  • WASHINGTON, May 2, 2024 /PRNewswire/ -- The Alliance for Gout Awareness today released a resource guide to help patients navigate the physical and mental toll of gout, a form of arthritis that affects over 9 million Americans.
  • The paper features resources from the Alliance for Gout Awareness and its partners to address four key topics:

US FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection, Boehringer Ingelheim's interchangeable* biosimilar to Humira®

Retrieved on: 
Wednesday, May 1, 2024

"Many patients are treated with high-concentration adalimumab formulations, and we are excited to add this new option to our approved citrate-free Cyltezo and Adalimumab-adbm offerings."

Key Points: 
  • "Many patients are treated with high-concentration adalimumab formulations, and we are excited to add this new option to our approved citrate-free Cyltezo and Adalimumab-adbm offerings."
  • "The flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicines."
  • "We welcome the introduction of this additional formulation to expand the array of options available to our community."
  • The FDA approval is based, in part, on data from clinical trial VOLTAIRE-HCLF , a Phase I clinical trial comparing the bioavailability of high-concentration and low-concentration formulations of adalimumab-adbm.

Space-Made Fibers and Novel Biotech Among Research Returning to Earth After Successful Space Station Mission

Retrieved on: 
Tuesday, April 30, 2024

KENNEDY SPACE CENTER, Fla., April 30, 2024 /PRNewswire/ -- Research on a novel vision loss therapy and space-manufactured optical fibers were among the nearly 565 pounds of science and technology payloads sponsored by the International Space Station (ISS) National Laboratory that splashed down off the Florida coast Tuesday morning as NASA concluded SpaceX's 30th Commercial Resupply Services (CRS) mission.

Key Points: 
  • Encapsulate leveraged the microgravity environment of the space station to validate an automated tumor-on-a-chip system that grows patient-derived cancer cells to test chemotherapy drugs.
  • Using powdered protein could significantly reduce the mass of materials sent to space for manufacturing, allowing increased production at a lower cost.
  • From mid-February to mid-March, the company manufactured a total of more than seven miles (11.9 km) of optical fiber on station.
  • These are just a few of the investigations returning to Earth in the SpaceX Dragon capsule on this mission.